Medicines labeled for the same conditions
Alternatives to pramlintide
14 other medicines are given the same way (subcutaneous) and in the same FDA class as pramlintide or labeled mainly for the same use (type 2 diabetes); the others include 6 insulin analogs, 6 GLP-1 receptor agonists and 1 glucose-dependent insulinotropic polypeptide receptor agonist (FDA labels read October 8, 2026).
Which medicines are labeled for the same conditions as pramlintide?
Type 2 diabetes lists all 52 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Pramlintideamylin analog | this medicine | none listed | n/a | Yes | A presentation being discontinued |
| Tirzepatideglucose-dependent insulinotropic polypeptide receptor agonist | Type 2 diabetes | none listed | $538.68 per mL 10 mg/0.5 mL pen | Yes | No current entry |
| Insulin glargineinsulin analog | Type 2 diabetes, Type 1 diabetes | none listed | $2.90 per mL 100 pen | No | A presentation being discontinued |
| LiraglutideGLP-1 receptor agonist | Type 2 diabetes | 9 labelers | $31.41 per mL 2-pak 18 mg/3 mL | Yes | In shortage |
| Insulin aspartinsulin analog | Type 2 diabetes, Type 1 diabetes | none listed | $6.95 per mL 100 unit/mL vial | No | No current entry |
| Insulin lisproinsulin analog | Type 2 diabetes, Type 1 diabetes | none listed | $10.19 per mL 100 unit/mL kwikpen | No | A presentation being discontinued |
| SemaglutideGLP-1 receptor agonist | Type 2 diabetes | none listed | $331.99 per mL 0.25-0.5 mg/dose (2 mg/3 mL) pen | Yes | A presentation being discontinued |
| Insulin humaninsulin | Type 2 diabetes, Type 1 diabetes | none listed | $4.26 per mL 70-30 vial | No | No current entry |
| DulaglutideGLP-1 receptor agonist | Type 2 diabetes | none listed | $487.57 per mL 0.75 mg/0.5 mL pen | Yes | No current entry |
| Insulin degludecinsulin analog | Type 2 diabetes, Type 1 diabetes | none listed | $11.39 per mL 100 unit/mL pen | No | No current entry |
| ExenatideGLP-1 receptor agonist | Type 2 diabetes | 1 labeler | $300.17 per mL 10 mcg dose pen injection | No | No current entry |
| Insulin detemirinsulin analog | Type 2 diabetes, Type 1 diabetes | none listed | n/a | No | No current entry |
| Insulin glulisineinsulin analog | Type 2 diabetes, Type 1 diabetes | none listed | $8.16 per mL 100 unit/mL vial | No | No current entry |
| Insulin degludec and liraglutideGLP-1 receptor agonist | Type 2 diabetes | none listed | $85.89 per mL 100 unit-3.6 mg/mL pen | Yes | No current entry |
| Insulin glargine and lixisenatideGLP-1 receptor agonist | Type 2 diabetes | none listed | $57.06 per mL 100 unit-33 mcg/mL pen | No | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Pramlintide: the full record
- label, generics, price, shortages, recalls